Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
17.63
+0.24 (1.38%)
At close: Jun 26, 2026, 4:00 PM EDT
17.62
-0.01 (-0.06%)
After-hours: Jun 26, 2026, 5:08 PM EDT

Theravance Biopharma Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, Theravance Biopharma stock has a consensus rating of "Buy" and an average price target of $17.4. The average 1-year stock price forecast is 1.30% lower than the current stock price, while the lowest is $15 (-14.92%) and the highest is $21 (+19.12%).

Price Target: $17.4 (-1.30%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$15$17.4$17$21
Change-14.92%-1.30%-3.57%+19.12%
* Price targets were last updated on May 28, 2026.

Analyst Ratings

The average analyst rating for Theravance Biopharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingDec '25Jan '26Feb '26Mar '26Apr '26May '26
Strong Buy555333
Buy000000
Hold222433
Sell000000
Strong Sell000000
Total777766

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
JonesTrading
JonesTrading
Buy
Reiterates
$18$19
BuyReiterates$18$19+7.77%May 28, 2026
BTIG
BTIG
Buy
Maintains
$21
BuyMaintains$21+19.12%May 8, 2026
TD Cowen
TD Cowen
Hold
Reiterates
$15
HoldReiterates$15-14.92%May 8, 2026
B. Riley Securities
B. Riley Securities
Hold
Maintains
$14$17
HoldMaintains$14$17-3.57%Apr 7, 2026
Oppenheimer
Oppenheimer
Hold
Downgrades
$27$14
HoldDowngrades$27$14-22.46%Mar 5, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
84.13M
from 107.46M
Decreased by -21.71%
Revenue Next Year
96.83M
from 84.13M
Increased by 15.09%
EPS This Year
0.21
from -0.15
EPS Next Year
1.26
from 0.21
Increased by 497.62%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
55.31M51.35M57.42M64.38M107.46M84.13M
Revenue Growth
-23.03%-7.17%11.84%12.12%66.92%-21.71%
Gross Profit
-138.35M-12.05M16.80M26.74M70.05M81.36M
Gross Margin
-250.12%-23.46%29.26%41.53%65.18%96.70%
Operating Income
-237.64M-79.12M-53.65M-42.44M-3.60M16.90M
Net Income
-199.43M872.13M-55.19M-56.42M105.90M151.50M
EPS
-----0.150.21
Forward PE
----25.8383.95
Free Cash Flow
-115.85M24.00M-12.22M-42.00M-4.12M12.40M
No. Analysts
-----3
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High93.7M
Avg84.1M
Low77.4M

Revenue Growth

Revenue Growth202620272028
High
-12.8%
Avg
-21.7%
Low
-28.0%

EPS Forecast

EPS202620272028
High-
Avg0.21
Low-

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-